Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease

Neurologic Clinics

Volumn 33, Issue 1, 2015, Pages 1-17

  Mullin, Stephen ^a   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Lewy bodies; Mitochondrial dysfunction; Parkinson disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SNCA PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; EPIDEMIOLOGY; GENETIC RISK; GENETICS; HISTOLOGY; HUMAN; IN VITRO STUDY; LEWY BODY; MITOCHONDRION; NERVE DEGENERATION; NEUROTOXICITY; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SENESCENCE; SUBSTANTIA NIGRA; COMPLICATION; METABOLISM; MUTATION; PATHOLOGY;

ALPHA-SYNUCLEIN; GLUCOSYLCERAMIDASE; HUMANS; MUTATION; NERVE DEGENERATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SUBSTANTIA NIGRA;

EID: 84918528656     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.09.010     Document Type: Review

References (146)

1. Braak H, Tredici KD, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211. http://dx.doi.org/10. 1016/S0197-4580(02)00065-9.
2. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6): 1214-20.
3. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157(11):1015-22.
4. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142(8):820-7.
5. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45(12):2143-6.
6. Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012;27(3): 406-12. http://dx.doi.org/10.1002/mds.24892.
7. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62(3):378-82. http://dx.doi.org/10. 1001/archneur.62.3.378.
8. Markesbery WR, Jicha GA, Liu H, et al. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009;68(7):816-22. http://dx.doi.org/10. 1097/NEN.0b013e3181ac10a7.
9. Jellinger KA. Age-associated prevalence and risk factors of Lewy body pathology in a general population. Acta Neuropathol 2003;106(4):383-4. http://dx.doi. org/10.1007/s00401-003-0751-9.
10. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007;13(Suppl 3):S221-4. http://dx.doi.org/10. 1016/S1353-8020(08)70005-1.
11. Del Ser T, McKeith I, Anand R, et al. Dementia with lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15(11):1034-45.
12. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010;363(2):166-76. http://dx.doi.org/10.1056/NEJMra 0905980.
13. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377(9766):641-9. http://dx.doi.org/10.1016/S0140-6736(10)62345-8.
14. Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet 2012;8(3):e1002548. http://dx.doi.org/10.1371/journal. pgen.1002548.
15. Hernan MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52(3):276-84. http://dx.doi.org/10.1002/ana.10277.
16. Tanner CM, Ross GW, Jewell SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 2009;66(9):1106-13. http://dx.doi. org/10.1001/archneurol.2009.195.
17. Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord 2013;28(1):8-13. http://dx.doi.org/10.1002/mds.25150.
18. Ammal Kaidery N, Tarannum S, Thomas B. Epigenetic landscape of Parkinson's disease:emerging role in disease mechanisms and therapeuticmodalities. Neurotherapeutics 2013;10(4):698-708. http://dx.doi.org/10.1007/s13311-013-0211-8.
19. Jowaed A, Schmitt I, Kaut O, et al. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 2010;30(18):6355-9. http://dx.doi.org/10.1523/JNEUROSCI.6119- 09.2010.
20. Matsumoto L, Takuma H, Tamaoka A, et al. CpG demethylation enhances alphasynuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010;5(11):e15522. http://dx.doi.org/10.1371/journal.pone.0015522.
21. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinson's disease. J Biotechnol 2011;152(3):96-101. http://dx.doi.org/10. 1016/j.jbiotec.2011.01.023.
22. Minones-Moyano E, Porta S, Escaramis G, et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011;20(15):3067-78. http://dx.doi. org/10.1093/hmg/ddr210.
23. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
24. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-40. http://dx.doi.org/10.1038/42166.
25. Krüger R, Kuhn W, Mü ller T, et al. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson's disease. Nat Genet 1998;18(2):106-8. http://dx.doi.org/ 10.1038/ng0298-106.
26. Zarranz JJ, Alegre J, Esteban JG. The new mutation, E46K, of a-synuclein causes parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73.
27. Kiely AP, Asi YT, Kara E, et al. a-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013;125(5):753-69. http://dx.doi.org/10.1007/s00401-013-1096-7.
28. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013;28(6):811-3. http://dx.doi.org/10.1002/mds.25421.
29. Proukakis C, Dudzik CG, Brier T, et al. A novel a-synuclein missense mutation in Parkinson disease. Neurology 2013;80(11):1062-4. http://dx.doi.org/10.1212/ WNL.0b013e31828727ba.
30. Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease the state of the art. Prog Brain Res 2010;184:53-87. http://dx.doi.org/10.1016/S0079- 6123(10)84004-X.
31. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841. http://dx.doi.org/10. 1126/science.1090278.
32. Muenter MD, Forno LS, Hornykiewicz O. Hereditary form of parkinsonism-dementia. Ann Neurol 1998;43:768-81.
33. Miller DW, Hague SM, Clarimon J, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004;62(10): 1835-8.
34. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alphasynuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364(9440):1169-71. http://dx.doi.org/10.1016/S0140-6736(04)17104-3.
35. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364(9440): 1167-9. http://dx.doi.org/10.1016/S0140-6736(04)17103-1.
36. Tan CC, Yu JT, Tan MS, et al. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol Aging 2014; 35(5):941-57. http://dx.doi.org/10.1016/j.neurobiolaging.2013.11.019.
37. Pals P, Lincoln S, Manning J, et al. Alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 2004;56(4):591-5. http://dx.doi.org/10. 1002/ana.20268.
38. Krüger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 2001;45(5):611-7. http://dx.doi.org/10.1002/1531- 8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X.
39. Cabin DE, Shimazu K, Murphy D, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002;22(20):8797-807.
40. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and betasynucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004;101(41): 14966-71. http://dx.doi.org/10.1073/pnas.0406283101.
41. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25(1):239-52.
42. Murphy DD, Rueter SM, Trojanowski JQ, et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000;20(9):3214-20.
43. Hashimoto M, Hsu LJ, Xia Y, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/a-synuclein in vitro. Neuroreport 1999;10(4):717.
44. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010; 183:115-45. http://dx.doi.org/10.1016/S0079-6123(10)83007-9.
45. Cole NB, Murphy DD, Grider T, et al. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein a-Synuclein. J Biol Chem 2002; 277(8):6344-52.
46. Winner B, Melrose HL, Zhao C, et al. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 2011;41(3):706-16. http:// dx.doi.org/10.1016/j.nbd.2010.12.008.
47. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000;97(2):571-6.
48. Ghosh D, Mondal M, Mohite GM, et al. The Parkinson's disease-associated H50Q mutation accelerates a-synuclein aggregation in vitro. Biochemistry 2013;52(40):6925-7. http://dx.doi.org/10.1021/bi400999d.
49. Pandey JP. Genomewide association studies and assessment of risk of disease. N Engl J Med 2010;363(21):2076-7. http://dx.doi.org/10.1056/ NEJMc1010310#SA1 [author reply: 2077].
50. Narhi L. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999;274(14):9843-6. http://dx.doi.org/10.1074/jbc. 274.14.9843.
51. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001;40(38):11604-13.
52. Kosaka K. Diffuse lewy body disease in Japan. J Neurol 1990;237(3):197-204. http://dx.doi.org/10.1007/BF00314594.
53. Dickson DW, Crystal H, Mattiace LA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 1989;78(6):572-84.
54. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152(4):879-84.
55. Prusiner SB. Nobel lecture: prions. Proc Natl Acad Sci U S A 1998;95(23): 13363-83. http://dx.doi.org/10.1073/pnas.95.23.13363.
56. Li Y, Sekine T, Funayama M, et al. Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol Aging 2014;35(4): 935.e3-8. http://dx.doi.org/10.1016/j.neurobiolaging.2013.09.019.
57. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14(5): 504-6. http://dx.doi.org/10.1038/nm1747.
58. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332(17):1118-24. http://dx.doi.org/10.1056/NEJM199504273321702.
59. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106(31):13010-5. http://dx.doi.org/10.1073/pnas.0903691106.
60. Hansen C, Angot E, BergstromAL, et al. a-Synuclein propagates frommouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;121(2):715-25. http://dx.doi.org/10.1172/JCI43366.
61. Luk KC, Kehm V, Carroll J, et al. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338(6109):949-53. http://dx.doi.org/10.1126/science.1227157.
62. Majeski AE, Dice JF. Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol 2004;36(12):2435-44. http://dx.doi.org/10.1016/j.biocel. 2004.02.013.
63. Anglade P, Vyas S, Hirsch EC, et al. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 1997;12(3):603-10.
64. Dice JF. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem Sci 1990;15(8):305-9.
65. Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004;305(5688): 1292-5. http://dx.doi.org/10.1126/science.1101738.
66. Webb JL, Ravikumar B, Atkins J, et al. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003;278(27):25009-13. http:// dx.doi.org/10.1074/jbc.M300227200.
67. Spencer B, Potkar R, Trejo M, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009;29(43):13578-88. http:// dx.doi.org/10.1523/JNEUROSCI.4390-09.2009.
68. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging 2010; 31(6):953-68. http://dx.doi.org/10.1016/j.neurobiolaging.2008.07.008.
69. Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008;28(33):8189-98. http://dx.doi.org/10.1523/ JNEUROSCI.2218-08.2008.
70. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372(9645):1263-71. http://dx.doi.org/10.1016/S0140-6736(08) 61522-6.
71. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73(4): 313-21. http://dx.doi.org/10.1006/mgme.2001.3201.
72. Varkonyi J, Simon Z, Soos K, et al. Gaucher disease type I complicated with Parkinson's syndrome. Haematologia (Budap) 2002;32(3):271-5.
73. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89(9):691-4.
74. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006; 36(3):426-8. http://dx.doi.org/10.1016/j.bcmd.2006.02.004.
75. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012;78(6):417-20. http://dx. doi.org/10.1212/WNL.0b013e318245f476.
76. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011;46(1):95-102. http://dx.doi.org/10.1016/j.bcmd.2010. 10.006.
77. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361(17):1651-61. http://dx.doi.org/10.1056/NEJMoa0901281.
78. McNeill A, Duran R, Hughes DA, et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012;83(8):853-4. http://dx.doi.org/10.1136/jnnp- 2012-302402.
79. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012;11(11):986-98. http://dx.doi.org/10.1016/S1474-4422(12)70190-4.
80. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012;72(3):455-63. http://dx. doi.org/10.1002/ana.23614.
81. Cullen V, Sardi SP, Ng J, et al. Acid b-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter a-synuclein processing. Ann Neurol 2011;69(6):940-53. http://dx.doi.org/10.1002/ana.22400.
82. Cleeter MW, Chau KY, Gluck C, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013; 62(1):1-7. http://dx.doi.org/10.1016/j.neuint.2012.10.010.
83. Manning-Bog AB, Schü le B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009;30(6):1127-32. http://dx.doi.org/10.1016/j.neuro.2009.06.009.
84. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and asynuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146(1):37-52. http://dx.doi.org/10.1016/j.cell.2011.06.001.
85. Osellame LD, Rahim AA, Hargreaves IP, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 2013;17(6):941-53. http://dx.doi.org/10.1016/j.cmet.2013.04.014.
86. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014; 137(Pt 5):1481-95. http://dx.doi.org/10.1093/brain/awu020.
87. Maegawa GH, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284(35):23502-16. http://dx.doi.org/10.1074/jbc.M109.012393.
88. Bendikov-Bar I, Maor G, Filocamo M, et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis 2013;50(2): 141-5. http://dx.doi.org/10.1016/j.bcmd.2012.10.007.
89. Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51(3): 296-301.
90. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600. http://dx.doi.org/10.1016/j.neuron.2004.10.023.
91. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4): 601-7. http://dx.doi.org/10.1016/j.neuron.2004.11.005.
92. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76(4):672-80. http://dx.doi.org/10.1086/429256.
93. Sierra M, Gonzalez-Aramburu I, Sanchez-Juan P, et al. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Mov Disord 2011;26(13):2343-6. http://dx.doi.org/10.1002/mds.23965.
94. Correia Guedes L, Ferreira JJ, Rosa MM, et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010;16(4):237-42. http://dx.doi.org/10.1016/j.parkreldis.2009.11.004.
95. Dachsel JC, Behrouz B, Yue M, et al. A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord 2010;16(10):650-5. http://dx.doi.org/10.1016/j.parkreldis.2010.08.018.
96. Tong Y, Giaime E, Yamaguchi H, et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener 2012;7:2. http://dx.doi.org/10.1186/1750-1326-7-2.
97. Ren Y, Liu W, Jiang H, et al. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005;280(40):34105-12. http://dx.doi.org/10.1074/jbc.M503483200.
98. Piccoli G, Condliffe SB, Bauer M, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011;31(6):2225-37. http://dx.doi.org/10.1523/JNEUROSCI.3730-10.2011.
99. Liu G, Zhang C, Yin J, et al. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 2009;454(3):187-92. http://dx.doi.org/10.1016/ j.neulet.2009.02.056.
100. Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal 2012;5(207):pe2. http://dx.doi.org/10.1126/ scisignal.2002680.
101. Ujiie S, Hatano T, Kubo SI, et al. LRRK2 I2020T mutation is associated with tau pathology. Parkinsonism Relat Disord 2012;18(7):819-23. http://dx.doi.org/10.1016/j.parkreldis.2012.03.024.
102. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128(Pt 12): 2786-96. http://dx.doi.org/10.1093/brain/awh667.
103. Gaig C, Marti MJ, Ezquerra M, et al. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 2007; 78(6):626-8. http://dx.doi.org/10.1136/jnnp.2006.107904.
104. Rajput A, Dickson DW, Robinson CA, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006;67(8):1506-8. http://dx.doi.org/10.1212/01.wnl.0000240220.33950.0c.
105. Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23(2):329-41. http://dx.doi.org/10.1016/j.nbd.2006.04.001.
106. Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9(10):1231-3. http://dx.doi.org/10.1038/ nn1776.
107. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7(1):97-109. http://dx.doi.org/10.1016/S1474- 4422(07)70327-7.
108. Chiueh CC, Markey SP, Burns RS, et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 1984;20(3):548-53.
109. Langston JW, Quik M, Petzinger G, et al. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000;47(4 Suppl 1):S79-89.
110. Sherer TB, Richardson JR, Testa CM, et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007;100(6):1469-79. http://dx.doi.org/10.1111/j.1471- 4159.2006.04333.x.
111. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3(12): 1301-6. http://dx.doi.org/10.1038/81834.
112. Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50(5):1346-50.
113. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1(8649):1269.
114. Hatano Y, Li Y, Sato K, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004;56(3):424-7. http://dx.doi.org/10.1002/ana.20251.
115. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304(5674): 1158-60. http://dx.doi.org/10.1126/science.1096284.
116. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996;47(1):160-6.
117. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-8. http://dx.doi.org/10.1038/33416.
118. Dupuis L. Mitochondrial quality control in neurodegenerative diseases. Biochimie 2014;100:177-83. http://dx.doi.org/10.1016/j.biochi.2013.07.033.
119. McLelland GL, Soubannier V, Chen CX, et al. Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J 2014;33(4):282-95. http://dx.doi.org/10.1002/embj.201385902.
120. Wood-Kaczmar A, Gandhi S, Yao Z, et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 2008;3(6):e2455. http://dx.doi.org/10.1371/journal.pone.0002455.
121. Cui M, Tang X, Christian WV, et al. Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. J Biol Chem 2010;285(15):11740-52. http://dx.doi.org/10.1074/jbc.M109.066662.
122. Lutz AK, Exner N, Fett ME, et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem 2009;284(34): 22938-51. http://dx.doi.org/10.1074/jbc.M109.035774.
123. Papkovskaia TD, Chau KY, Inesta-Vaquera F, et al. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet 2012;21(19):4201-13. http://dx.doi.org/10.1093/hmg/dds244.
124. Mortiboys H, Johansen KK, Aasly JO, et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010; 75(22):2017-20. http://dx.doi.org/10.1212/WNL.0b013e3181ff9685.
125. Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53Talpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011; 286(12):10814-24. http://dx.doi.org/10.1074/jbc.M110.132514.
126. Orsucci D, Ienco EC, Mancuso M. POLG1-related and other "mitochondrial Parkinsonisms": an overview. J Mol Neurosci 2011;44:17-24.
127. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006;38(5):515-7. http://dx.doi.org/10.1038/ng1769.
128. Hudson G, Nalls M, Evans JR, et al. Two-stage association study andmeta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 2013;80:2042-58.
129. Payne BA, Wilson IJ, Hateley CA, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011;43(8):806-10. http://dx.doi.org/10.1038/ng.863.
130. Tisch S, Brew BJ. HIV, HAART, and Parkinson's disease: co-incidence or pathogenetic link? Mov Disord 2010;25:2257-8.
131. Tisch S, Brew B. Parkinsonism in hiv-infected patients on highly active antiretroviral therapy. Neurology 2009;73(5):401-3. http://dx.doi.org/10.1212/WNL.0b013e3181b04b0d.
132. Cole NB, Dieuliis D, Leo P, et al. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res 2008;314(10):2076-89. http://dx.doi.org/10.1016/j.yexcr.2008.03.012.
133. Shavali S, Brown-Borg HM, Ebadi M, et al. Mitochondrial localization of alphasynuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 2008; 439(2):125-8. http://dx.doi.org/10.1016/j.neulet.2008.05.005.
134. Nakamura K, Nemani VM,Wallender EK, et al. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci 2008;28(47):12305-17. http://dx.doi.org/10.1523/JNEUROSCI.3088-08.2008.
135. Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157(2):401-10.
136. Martin LJ. Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci 2012;107:355-415. http://dx.doi.org/10.1016/B978-0-12-385883-2.00005-9.
137. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008;283(14):9089-100. http://dx.doi.org/10.1074/jbc.M710012200.
138. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alphasynuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8(6):600-6. http://dx.doi.org/10.1038/nm0602-600.
139. Moussa CE, Mahmoodian F, Tomita Y, et al. Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun 2008;365(4):833-9. http://dx.doi.org/10.1016/j.bbrc.2007.11.075.
140. Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37-42. http://dx.doi.org/10.1007/s00415-005-4008-5.
141. McCarthy A, McKinley J, Lynch T. The inherent susceptibility of dorsal motor nucleus cholinergic neurons to the neurodegenerative process in Parkinson's Disease. Front Neurol 2012;3:189. http://dx.doi.org/10.3389/fneur.2012.00189.
142. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985;18(5):552-5. http://dx.doi.org/10.1002/ ana.410180507.
143. Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122(Pt 8):1437-48.
144. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2013;288(15):10736-41. http://dx.doi.org/10.1074/jbc.R112.410530.
145. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009;72(6):578-9. http://dx.doi.org/10.1212/01.wnl.00003 44171.22760.24.
146. Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010;67(5):600-6. http://dx.doi.org/10.1002/ ana.21937.